Announcements Trials
Browse Landscape

Phase

Phase 1 17Phase 2 14Phase 1/2 8Phase 3 4Phase NA 3

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 198Breast 130Head & Neck 22Tumor-Agnostic 4NET 3Endocrine 3CNS 2Thoracic 1Other solid neoplasm 1Other neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Adenocarcinoma 3Neoplasms 2Neoplasm Metastasis 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Capecitabine × Tumor-Agnostic × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

EMD Serono

Phase 3 Completed
499 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00548548 2017-06-14

AVAGAST

Genentech, Inc.

Phase 3 Completed
774 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡